Effects of esketamine on the prevention of postpartum depression in cesarean section patients

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100053422

Enrollment

Unknown

Registered

2021-11-20

Start date

2021-11-15

Completion date

Unknown

Last updated

2022-09-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postpartum depression

Interventions

control group:esketamine group

experimental group:Esketamine hydrochloride

Eligibility

Sex/Gender

Female

Age

22 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 50 years, gestational age >= 36 weeks singleton; 2. ASA I-II grade, subarachnoid block and epidural catheter placement; 3. Use an intravenous patient-controlled analgesia pump after operation; 4. Parturients who have signed the informed consent form and agreed to join the group.

Exclusion criteria

Exclusion criteria: 1. Not fasting and fasting; 2. Change to general anesthesia; change to cesarean section for painless delivery; 3. The fetus has congenital diseases; high blood pressure; 4. Mental disorder before surgery; drug or alcohol abuse; esketamine allergy; communication disorder.

Design outcomes

Primary

Measure	Time frame
Incidence of postpartum depression;Inflammatory cytokines;Hormone levels;	—

Countries

China

Contacts

Public ContactXu Shixi

Zhongda Hospital affiliated to Southeast University

xsx1987112@126.com+86 15261873964

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 9, 2026